NPRL2 and lung cancer: None of the candidate TSGs (CACNA2D2, PL6, 101F6, NPRL2, BLU, RASSF1, FUS1, HYAL2, HYAL1 and SEMA3B) showed a frequent mutation rate in lung cancer samples however, suggesting that they may function in dose-dependent manner (see [1] for review).